Schistosoma mansoni: preclinical studies with 9-Acridanone-hydrazones in Cebus monkeys experimentally infected.
Derivatives of acridine (9-Acridanone-hydrazones) were tested in Cebus monkeys experimentally infected with Schistosoma mansoni, at the dosages of 50, 25, and 12.5 mg/kg (p.o., single dose). At least, four compounds seemed to be very promising, promoting alterations in the oogram and reducing the worm burden drastically, even at the lowest dose (12.5 mg/kg). No side effects could be detected after drug administration.
Coelho
P M
PM
Departamento de Parasitologia, Universidade Federal de Minas Gerais (ICB/UFMG), Belo Horizonte, Brasil.
Pereira
L H
LH
D000166:Acridines / Q000627:therapeutic use*; D000818:Animals; D002428:Cebus; D004353:Drug Evaluation, Preclinical; D005260:Female; D008297:Male; D010063:Ovum / Q000187:drug effects; D012550:Schistosoma mansoni / Q000187:drug effects; D012555:Schistosomiasis mansoni / Q000188:drug therapy*; D012556:Schistosomicides / Q000627:therapeutic use*
D000166:Acridines; D012556:Schistosomicides